Docetaxel treatment induces cell death by activating checkpoint kinase- and SPOP-mediated ELK3 degradation; however, PCa cells with SPOP depletion or mutation exhibit resistance to this mechanism 50. This evidence concerns the gene ELK3 and posterior cortical atrophy.